|Day Low/High||14.70 / 15.00|
|52 Wk Low/High||12.45 / 21.69|
Furthers Mission to Address Unmet Medical Needs Across the Globe
The most recent short interest data was recently released for the 03/31/2016 settlement date, and Albany Molecular Research Inc is one of the most shorted stocks of the Russell 3000, based on 20.08 "days to cover" versus the median component at 6.16. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Trade-Ideas LLC identified Albany Molecular Research (AMRI) as a weak on high relative volume candidate
Investors considering a purchase of Albany Molecular Research, Inc. shares, but tentative about paying the going market price of $14.70/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
- Pfizer Executive Brings Additional Pharmaceutical Industry Experience and Expertise to the Board -
Collaboration to Enhance Application of Nanotechnology in Integrated Drug Discovery Setting
Eagle Pharmaceuticals ("Eagle" or the "Company") (NASDAQ:EGRX) and AMRI (NASDAQ:AMRI) today announced that they have entered into an agreement to jointly develop and manufacture several select and complex parenteral drug...
First Alcohol-Free Formulation Provides U.S. Patients with Alternative to Traditional Docetaxel Injection Treatment